car-t therapy in aml: why has there been a lack of success?
Published 6 months ago • 275 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
2:23
an update on car-t therapy in aml: challenges & emerging strategies
-
2:08
challenges with car-t therapy in aml & insights into if-better-gated car-t cells
-
1:44
challenges in developing car-t therapy for aml
-
1:34
cctx-001: a novel car-t therapy for aml
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
2:30
new leukemia treatment gives hope to cancer sufferers
-
41:39
2022 wmif | the cell therapy landscape | car-t to stem cells
-
3:14
car t-cell therapy explained (manufacturing process & how it works)
-
3:43
the future of car-t therapy
-
25:18
addressing the major challenges to car-t therapy in aml
-
3:08
car t-cell therapy: the patient's perspective
-
2:11
future prospects for car-t cell therapy in aml
-
1:25
the role of car-t therapy and hsct in autoimmune disorders
-
1:16
hurdles to car-t therapy for mds & aml: t-cell fitness & lack of a uniform target antigen
-
3:15
key updates in car-t therapy from eha 2022
-
1:08
the benefits of car-t therapy in 2l over 3l in r/r dlbcl
-
1:37
can we target aml with car t-cells?
-
1:41
current and emerging indications for car-t therapy in lbcl
-
3:39
car t-cells and crispr: the future of aml treatment
-
2:51
the emergence of novel antibodies, car-t and car-nk therapies in aml
-
1:10
unmet needs in car-t therapy: options for patients who progress during the manufacturing process
-
0:52
the future of car t-cell therapy for aml